EL: AI Eyewear Partnerships And Expanded Markets Will Support Future Upside

The analyst price target for EssilorLuxottica Société anonyme has been reduced in line with a lower fair value estimate, with recent cuts in Street targets ranging from about €2 to €110, as analysts factor in more moderate assumptions for growth, profitability, and future P/E multiples.

Analyst Commentary

Recent Street research on EssilorLuxottica Société anonyme points to a more cautious but still engaged analyst community, with several firms revising price targets while maintaining existing ratings. For investors, the main story is how these changes reflect updated assumptions around execution, growth, and what valuation multiples the stock may reasonably carry.

Bullish Takeaways

Some bullish analysts continue to see upside potential in EssilorLuxottica shares, as shown by Overweight ratings being maintained even as targets are reset to €305 and €225, which still sit comfortably above many historical levels investors may be familiar with.
Maintaining Overweight ratings alongside reduced targets suggests confidence in the company’s long term fundamentals, with the revisions focused more on calibrating expectations than on a shift in conviction about EssilorLuxottica’s positioning.
The range of targets, including those over €300 from large institutions such as JPMorgan, indicates that a segment of the Street still assigns a relatively full P/E multiple to EssilorLuxottica. This implies that execution on existing plans could be enough to support a premium valuation.
Repeated coverage and updated models from major banks also signal that EssilorLuxottica remains an important stock for global consumer and luxury portfolios, which can help sustain liquidity and institutional interest.

Bearish Takeaways

Bearish analysts have trimmed price targets across several reports, including reductions to around €181 and €225, pointing to reduced assumptions for growth, profitability, or future P/E multiples relative to earlier models.
The presence of Hold and neutral ratings, particularly around the €181 area, shows that some on the Street see EssilorLuxottica as more fairly valued, with less room for upside if execution or end market demand comes in below prior expectations.
The sequence of downward adjustments, including cuts of €50 and €85 referenced in recent research, highlights ongoing caution about how much investors should be willing to pay for the stock if operational delivery or margin trends remain more moderate.
With targets spanning a wide band, from the low €180s to above €300, dispersion in analyst views underscores uncertainty around the appropriate valuation framework for EssilorLuxottica and raises the risk of sentiment swings if future updates do not align with the more optimistic models.

What’s in the News for EssilorLuxottica

Leonardo Maria Del Vecchio is pressing the Delfin board to back a multi billion euro plan to buy out his siblings' combined stake, a move that could increase his control over family assets held through Delfin, which owns a significant stake in EssilorLuxottica and has influence across Italian financial institutions (source: recent Delfin coverage).
EssilorLuxottica and Meta announced the launch of Meta Glasses, a new collection of AI glasses that broadens the existing portfolio that includes Ray Ban Meta, Oakley Meta and Meta Ray Ban Display, with price points for the new collection starting at $299 and availability across multiple markets and retailers including Meta.com, LensCrafters and Sunglass Hut (source: company announcement).
The Meta Glasses collection includes 3 prescription ready styles, with rectangle, square and oval shapes and lens options such as clear, sun and Transitions lenses. It is intended to reach a wider base of consumers interested in AI eyewear across the US, Canada, the UK, France, Italy, Germany, Spain and other European countries, with additional markets to follow (source: company announcement).
EssilorLuxottica and Applied Materials agreed a long term joint development partnership focused on next generation intelligent optical systems for augmented reality and AI powered smart eyewear. The partnership combines EssilorLuxottica’s lens and frame capabilities with Applied Materials’ materials engineering and waveguide technologies in a dedicated collaboration lab in Silicon Valley (source: company announcement).
EssilorLuxottica shareholders approved all 30 resolutions at the General Meeting, including a €4.00 dividend per share for the financial year ended December 31, 2025, an ex dividend date of May 5, 2026, a payment date of June 3, 2026 and an option to receive the dividend in shares at a price of €175.06 per share (source: company meeting results).

Valuation Changes for EssilorLuxottica Société anonyme

Fair Value: cut from €282.39 to €261.48, a reduction of about 7%, reflecting more moderate assumptions built into the model.
Discount Rate: trimmed slightly from 7.35% to 7.22%, indicating only a small adjustment to the required return used in the valuation.
Revenue Growth: eased from 9.33% to 9.00%, a modest step down in projected top line expansion for EssilorLuxottica in the updated scenario.
Net Profit Margin: reduced from 9.78% to 9.66%, pointing to slightly lower expected profitability on future euro revenue.
Future P/E: lowered from 45.0x to 42.4x, suggesting the stock is now modeled with a more restrained valuation multiple on future earnings.

0 views

Key Takeaways

Ongoing innovation in vision solutions and smart eyewear, along with strategic acquisitions, enhances competitive advantage and supports future market share and profitability.
Global expansion, supply chain diversification, and direct-to-consumer initiatives drive top-line growth, operational resilience, and recurring revenue opportunities.
Heavy investment in innovative eyewear and premium segments exposes EssilorLuxottica to technology, regulatory, economic, and margin risks amid intensifying competition and global cost pressures.

Catalysts

About EssilorLuxottica Société anonyme

Designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, the Middle East, Africa, Europe, Latin America, and the Asia-Pacific.What are the underlying business or industry changes driving this perspective?

Strong pipeline of innovation in myopia management solutions (Stellest 2.0, DOT technology) and leadership in addressing rising vision disorders among children globally positions EssilorLuxottica to capture outsized growth from increasing myopia incidence, directly supporting future revenue and market share gains.
Expanding global presence, especially in Asia and Latin America, leverages the growing middle class and improved healthcare access in emerging markets, opening new high-growth channels and supporting sustained top-line expansion.
Investments in smart eyewear, AI-enabled vision solutions, and MedTech (Ray-Ban Meta, Oakley Meta, Nuance Audio, acquisition of Optegra Eye Clinics) capitalize on long-term demand for technologically advanced and personalized eye health platforms, catalyzing product mix upgrades and higher ASPs, which will benefit gross margin and future earnings.
Ongoing vertical integration and supply chain diversification (new production facilities in France, Thailand, Laos, Mexico) improve operational efficiency and mitigate tariff/regulatory headwinds, preserving or expanding operating margins and providing resilience to exogenous shocks.
Accelerating direct-to-consumer and subscription-based channels (notably in Europe and North America), plus deeper engagement with healthcare professionals, enable stronger customer acquisition, higher recurring revenues, and long-term margin improvement, supporting net income and cash flow growth.

EssilorLuxottica Société anonyme Earnings and Revenue Growth

EssilorLuxottica Société anonyme Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming EssilorLuxottica Société anonyme's revenue will grow by 9.0% annually over the next 3 years.
Analysts assume that profit margins will increase from 8.1% today to 9.7% in 3 years time.
Analysts expect earnings to reach €3.6 billion (and earnings per share of €7.89) by about June 2029, up from €2.3 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as €4.7 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 42.4x on those 2029 earnings, up from 32.6x today. This future PE is greater than the current PE for the GB Medical Equipment industry at 22.4x.
Analysts expect the number of shares outstanding to grow by 0.44% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.22%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The rapid shift towards disruptive optical technologies, such as smart eyewear and AI-enabled glasses, carries substantial execution and adoption risks-if EssilorLuxottica is unable to maintain product relevance, successfully commercialize innovations, or keep pace with technology leaders, it could suffer from slower revenue growth and margin dilution, especially as wearables have been acknowledged as margin dilutive despite their sales momentum.
Intensifying global tariff headwinds and persistent inflationary pressures (notably in the U.S. market) could erode gross margins and net income, with recent results already showing 80-90 basis points of margin dilution and management warning that mitigation strategies like price increases and supply chain relocation may only gradually offset these costs.
The company's aggressive investment in MedTech and a growing assortment of premium/luxury segments (e.g., AI glasses, Stellest lenses, hearing aid eyewear) could make it increasingly vulnerable to economic downturns and cyclical spending contractions, thus exposing revenues and profitability to swings in discretionary consumer income and global macro risks.
EssilorLuxottica's reliance on being the market leader in emerging medical and wearable categories heightens its exposure to tightening regulatory scrutiny and slow or fragmented reimbursement/approval processes (e.g., FDA approval for Stellest lenses), potentially delaying new revenue streams and pressuring earnings if regulatory hurdles or commercialization setbacks occur.
The ongoing expansion of integrated, direct-to-consumer channels and major retail rollouts raises the risk of operational complexity and execution missteps, while at the same time global e-commerce and lower-cost competitors are driving greater price transparency and margin compression-pressuring EssilorLuxottica's long-term revenue growth and its ability to sustain premium pricing.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of €261.48 for EssilorLuxottica Société anonyme based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €361.0, and the most bearish reporting a price target of just €180.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €36.9 billion, earnings will come to €3.6 billion, and it would be trading on a PE ratio of 42.4x, assuming you use a discount rate of 7.2%.
Given the current share price of €164.05, the analyst price target of €261.48 is 37.3% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on EssilorLuxottica Société anonyme?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

EL: Expansion Into New Optical Markets Will Drive Measured MedTech Momentum